Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study
DOI:
https://doi.org/10.2340/actadv.v105.44165Keywords:
atopic dermatitis, dose reduction, Janus kinase inhibitors, daily practice, PROMs, prospective studies., observational studyAbstract
Janus kinase 1 (JAK1) inhibitors are effective for atopic dermatitis, but carry risks of adverse events. Dose reduction may mitigate these risks, although real-world evidence of dose reduction strategies is limited. This prospective, real-world study investigated JAK1 inhibitor dose reduction among 60 adults with controlled atopic dermatitis treated with abrocitinib or upadacitinib for ≥ 3 months. Doses were halved or administered every other day, as capsules cannot be split. Patients could resume their original dose if needed. The primary outcome was the proportion of patients maintaining the reduced dose at week 12. Secondary outcomes included physician- and patient-reported measures at baseline, and weeks 4, 8, and 12, analysed using linear mixed-effects models. At week 12, 80% (48/60) maintained the reduced dose. All outcomes remained within treat-to-target goals for atopic dermatitis at week 12, except for POEM (mean 8.87, 95% CI 7.43–10.31). While disease activity was significantly increased at week 8, no changes were seen at week 12. Absolute changes did not exceed the minimal clinically important difference. All 8 patients who resumed their initial dose regained disease control at week 12. In conclusion, JAK1 inhibitor dose reduction was feasible in 80% of patients without a clinically meaningful increase in disease activity.
Downloads
References
NVDV. Conventionele systemische immunosuppressieve therapie CE. Utrecht: NVDV, 2019.
Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol 2021; 157: 1165–1173. DOI: https://doi.org/10.1001/jamadermatol.2021.2830
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151–2168. DOI: https://doi.org/10.1016/S0140-6736(21)00588-2
Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 1333–1343. DOI: https://doi.org/10.1001/jamadermatol.2020.3260
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169–2181. DOI: https://doi.org/10.1016/S0140-6736(21)00589-4
Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 863–873. DOI: https://doi.org/10.1001/jamadermatol.2020.1406
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396: 255–266. DOI: https://doi.org/10.1016/S0140-6736(20)30732-7
Olydam JI, Schlösser AR, Custurone P, Nijsten TEC, Hijnen D. Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis. J Eur Acad Dermatol Venereol 2023; 37: 2537–2542. DOI: https://doi.org/10.1111/jdv.19378
Schlösser AR, Boeijink N, Olydam J, Nijsten TEC, Hijnen D. Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort. J Eur Acad Dermatol Venereol 2024; 38: 384–392. DOI: https://doi.org/10.1111/jdv.19581
Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol 2021; 35: 1797–1810. DOI: https://doi.org/10.1111/jdv.17351
Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther 2022; 35: e15636. DOI: https://doi.org/10.1111/dth.15636
Drucker AM, Lam M, Elsawi R, Prieto-Merino D, Malek R, Ellis AG, et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol 2024; 190: 184–190. DOI: https://doi.org/10.1093/bjd/ljad393
NVDV. Standpunt voorschrijven upadacitinib bij volwassen patiënten en adolescenten vanaf 12 jaar met matig tot ernstig constitutioneel eczeem. 2022. Available from: https://nvdv.nl/storage/app/media/uploaded-files/NTvDV_01_2022_NVDV-Standpunt%20voorschrijven%20%20upadacitinib.pdf
NVDV. Abrocitinib bij volwassen patienten met matig tot ernstig constitutioneel eczeem (standpunt). 2022. Avaliable from nvdv-standpunt-abrocitinib-bij-volwassen-patieenten-met-matig-tot-ernstig-constitutioneel-eczeem.pdf
Medicijnkosten: Zorginstituut Nederland. 2023. Available from: https://www.medicijnkosten.nl/
Chang PH, Huang SF, Chang PS, Yu Y. Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications. J Dermatol 2021; 48: 1631–1639. DOI: https://doi.org/10.1111/1346-8138.16116
Gao Q, Zhao Y, Zhang J. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Heliyon 2023; 9: e16704. DOI: https://doi.org/10.1016/j.heliyon.2023.e16704
Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the Phase II and Phase III clinical trial program. Am J Clin Dermatol 2021; 22: 693–707. DOI: https://doi.org/10.1007/s40257-021-00618-3
Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol 2022; 158: 404–413. DOI: https://doi.org/10.1001/jamadermatol.2022.0029
Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis 2019; 78: 171–178. DOI: https://doi.org/10.1136/annrheumdis-2018-213271
Spuls PI, Gerbens LAA, Apfelbacher CJ, Wall D, Arents BWM, Barbarot S, et al. The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: an initiative to harmonize data collection across national atopic eczema photo- and systemic therapy registries. J Invest Dermatol 2017; 137: 2014–2016. DOI: https://doi.org/10.1016/j.jid.2017.05.014
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. 1980. Acta Derm Venereol 1980; Suppl 92: 44-47. DOI: https://doi.org/10.2340/00015555924447
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 101: adv00402. DOI: https://doi.org/10.2340/00015555-3751
Chen R, Loman L, van der Gang LF, Sloot MM, de Bruin-Weller MS, Schuttelaar MLA. Assessing disease control in patients with atopic dermatitis by using the Atopic Dermatitis Control Tool in daily practice. Dermatology 2024; 240: 732–738. DOI: https://doi.org/10.1159/000541466
Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin 2020; 36: 367–376. DOI: https://doi.org/10.1080/03007995.2019.1699516
Stuart BL, Howells L, Pattinson RL, Chalmers JR, Grindlay D, Rogers NK, et al. Measurement properties of patient-reported outcome measures for eczema control: a systematic review. J Eur Acad Dermatol Venereol 2021; 35: 1987–1993. DOI: https://doi.org/10.1111/jdv.17335
Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99–106. DOI: https://doi.org/10.1111/j.1398-9995.2011.02719.x
Reich A, Riepe C, Anastasiadou Z, Mędrek K, Augustin M, Szepietowski JC, et al. Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch. Acta Derm Venereol 2016; 96: 978–980. DOI: https://doi.org/10.2340/00015555-2433
Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015; 230: 27–33. DOI: https://doi.org/10.1159/000365390
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol 2019; 19: 15. DOI: https://doi.org/10.1186/s12895-019-0095-3
Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol 2016; 74: 288–294. DOI: https://doi.org/10.1016/j.jaad.2015.09.062
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Initiative S. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806–808. DOI: https://doi.org/10.1136/bmj.39335.541782.AD
Williams HC, Schmitt J, Thomas KS, Spuls PI, Simpson EL, Apfelbacher CJ, et al. The HOME Core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol 2022; 149: 1899–1911. DOI: https://doi.org/10.1016/j.jaci.2022.03.017
Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326–1332. DOI: https://doi.org/10.1111/bjd.12590
Chen BL, Huang S, Dong XW, Wu DD, Bai YP, Chen YY. Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis. J Dermatolog Treat 2024; 35: 2397477. DOI: https://doi.org/10.1080/09546634.2024.2397477
AbbVie. Rinvoq: summary of product characteristics. European Medicines Agency (EMA), 2019: p. 47.
Pfizer. Cibinqo: summary of product characteristics. European Medicines Agency (EMA), 2021: p. 21.
Leventhal H, Cameron LD. The self-regulation of health and illness behaviour. Abingdon, UK: Routledge; 2003.
BioDay Eczema and Atopic Diseases Registry.Available from: https://bioday.nl/
Papi A, Ferreira DS, Agache I, Baraldi E, Beasley R, Brusselle G, et al. European Respiratory Society short guide-lines for the use of as-needed ICS/formoterol in mild asthma. Eur Respir J 2023; 62: 2300047. DOI: https://doi.org/10.1183/13993003.00047-2023
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Anne R. Schlösser, Anouk G.M. Caron, Merle S. den Ouden, Sara J. Baart, Louise A.A. Gerbens, Phyllis I. Spuls, Tamar E.C. Nijsten, Renske Schappin, Dirkjan Hijnen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
